Vaccines against tuberculosis: where are we and where do we need to go?
THM Ottenhoff, SHE Kaufmann - PLoS pathogens, 2012 - journals.plos.org
In this review we discuss recent progress in the development, testing, and clinical evaluation
of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has …
of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has …
Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis
T Prezzemolo, G Guggino, MP La Manna… - Frontiers in …, 2014 - frontiersin.org
With 1.4 million deaths and 8.7 million new cases in 2011, tuberculosis (TB) remains a
global health care problem and together with HIV and Malaria represents one of the three …
global health care problem and together with HIV and Malaria represents one of the three …
The Mycobacterium tuberculosis DosR Regulon Assists in Metabolic Homeostasis and Enables Rapid Recovery from Nonrespiring Dormancy
RL Leistikow, RA Morton, IL Bartek… - Journal of …, 2010 - Am Soc Microbiol
Mycobacterium tuberculosis survives in latently infected individuals, likely in a
nonreplicating or dormancy-like state. The M. tuberculosis DosR regulon is a genetic …
nonreplicating or dormancy-like state. The M. tuberculosis DosR regulon is a genetic …
Memory T Cells in Latent Mycobacterium tuberculosis Infection Are Directed against Three Antigenic Islands and Largely Contained in a CXCR3+CCR6+ Th1 …
An understanding of the immunological footprint of Mycobacterium tuberculosis (MTB) CD4
T cell recognition is still incomplete. Here we report that human Th1 cells specific for MTB …
T cell recognition is still incomplete. Here we report that human Th1 cells specific for MTB …
Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis
THM Ottenhoff, RH Dass, N Yang, MM Zhang… - 2012 - journals.plos.org
Tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), remains the leading cause
of mortality from a single infectious agent. Each year around 9 million individuals newly …
of mortality from a single infectious agent. Each year around 9 million individuals newly …
Mycobacterium tuberculosis: immune evasion, latency and reactivation
One-third of the global human population harbours Mycobacterium tuberculosis in dormant
form. This dormant or latent infection presents a major challenge for global efforts to …
form. This dormant or latent infection presents a major challenge for global efforts to …
Redox homeostasis in mycobacteria: the key to tuberculosis control?
Mycobacterium tuberculosis (Mtb) is a metabolically flexible pathogen that has the
extraordinary ability to sense and adapt to the continuously changing host environment …
extraordinary ability to sense and adapt to the continuously changing host environment …
Novel vaccination strategies against tuberculosis
P Andersen, SHE Kaufmann - Cold Spring …, 2014 - perspectivesinmedicine.cshlp.org
The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG
(Bacillus Calmette–Guérin) vaccine. Novel vaccination strategies are urgently needed to …
(Bacillus Calmette–Guérin) vaccine. Novel vaccination strategies are urgently needed to …
Tuberculosis biomarkers: from diagnosis to protection
New approaches to control tuberculosis (TB) worldwide are needed. In particular, new tools
for diagnosis and new biomarkers are required to evaluate both pathogen and host key …
for diagnosis and new biomarkers are required to evaluate both pathogen and host key …
For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection
A Dorhoi, ST Reece, SHE Kaufmann - Immunological reviews, 2011 - Wiley Online Library
Tuberculosis (TB) is a complex disease, and the success of the bacterium as an intracellular
pathogen is the outcome of its close and longstanding coevolution with the mammalian host …
pathogen is the outcome of its close and longstanding coevolution with the mammalian host …